SLC7A11 and cancer: Lower expression of SLC7A11 is associated with higher responses of cancer cells to arsenic trioxide, parthenolide, and raloxifene that inhibit the proliferation or migration of RCC cells and are a potential therapeutic strategy for RCC [61–63].